References
- Agid Y, Buzsáki G, Diamond DM et al. How can drug discovery for psychiatric disorders be improved? Nat. Rev. Drug Discov.6(3), 189–201 (2007).
- Sebat J, Lakshmi B, Malhotra D et al. Strong association of de novo copy number mutations with autism. Science316(5823), 445–449 (2007).
- Sullivan PF. The genetics of schizophrenia. PLoS Med.2(7), e212 (2005).
- Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systemic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet.39(1), 17–23 (2007).
- Ioannidis JP, Trikalinos TA, Khoury MJ. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am. J. Epidemiol.164(7), 609–614 (2006).
- Kim S, Xu X, Hecht A, Boyer TG. Mediator is a transducer of Wnt/β-catenin signaling. J. Biol. Chem.281(20), 14066–14075 (2006).
- Guglielmi B, van Berkum NL, Klapholz B et al. A high resolution protein interaction map of the yeast Mediator complex. Nucl. Acids Res.32(18), 5379–5391 (2004).
- Philibert RA. Recent research development in human genetics. In: Mediator Variation in Neuropsychiatric Illness. Research Signpost, Kerala, India 3, 1–19 (2005).
- Philibert RA, Bohle P, Secrest D et al. The association of the HOPA12bp polymorphism with schizophrenia in the NIMH genetics initiative for schizophrenia sample. Am. J. Med. Genet. B. Neuropsychiatr. Genet. (2007) (Epub ahead of print).
- Philibert RA. A meta-analysis of the association of the HOPA12bp polymorphism and schizophrenia. Psychiatr. Genet.16(2), 73–76 (2006).
- Castelo-Branco G, Arenas E. Function of Wnts in dopaminergic neuron development. Neurodegener. Dis.3(1–2), 5–11 (2006).
- Hong SK, Haldin CE, Lawson ND et al. The zebrafish kohtalo/trap230 gene is required for the development of the brain, neural crest, and pronephric kidney. Proc. Natl Acad. Sci. USA102(51), 18473–18478 (2005).
- Wang X, Yang N, Uno E et al. A subunit of the mediator complex regulates vertebrate neuronal development. Proc. Natl Acad. Sci. USA103(46), 17284–17289 (2006).
- De Ferrari GV, Moon RT. The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene25(57), 7545–7553 (2006).
- Miyaoka T, Seno H, Ishino H. Increased expression of Wnt-1 in schizophrenic brains. Schizophr. Res.38(1), 1–6 (1999).
- Zhang Y, Yu X, Yuan Y et al. Positive association of the human frizzled 3 (FZD3) gene haplotype with schizophrenia in Chinese Han population. Am. J. Med. Genet. B. Neuropsychiatr. Genet.129(1), 16–19 (2004).
- Alimohamad H, Sutton L, Mouyal J, Rajakumar N, Rushlow WJ. The effects of antipsychotics on β-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats. J. Neurochem.95(2), 513–525 (2005).
- Espinosa L, Inglés-Esteve J, Aguilera C, Bigas A. Phosphorylation by glycogen synthase kinase-3β down-regulates Notchactivity, a link for Notch and Wnt pathways. J. Biol. Chem.278(34), 32227–32235 (2003).
- Stefansson H, Steinthorsdottir V, Thorgeirsson TE, Gulcher JR, Stefansson K. Neuregulin 1 and schizophrenia. Ann. Med.36(1), 62–71 (2004).
- Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry60(2), 132–140 (2006).
- Lee I, Date SV, Adai AT, Marcotte EM. A probabilistic functional network of yeast genes. Science306(5701), 1555–1558 (2004).
Websites
- Schizophrenia Forum’s SchizophreniaGene (SzGene) website www.schizophreniaforum.org/res/sczgene
- Genetic Assocation Information Network (GAIN) website www.fnih.org/GAIN2/home_new.shtml